Liquidia (LQDA) FY25 earnings call

Liquidia Corporation reported strong full year 2025 results, driven by the rapid and successful launch of YUTREPIA, which quickly achieved profitability and significant market penetration. The company is focused on expanding YUTREPIA's clinical evidence and pipeline, including advancing L606 and exploring new indications, while maintaining a bullish outlook towards achieving $1 billion in sales by 2027 despite competitive developments and ongoing legal proceedings.